Drug Delivery

Drug Delivery

Floreat Medica Research & Development (R&D) is focused towards developing new products, improving existing products as well as drug delivery systems and expanding product applications.

In-house R&D forms the backbone of our operations. With almost 5-6% of the company turnover being invested towards R&D each year, our strategy focuses on:

  • Developing new drug formulations for existing and newer drug substances
  • Improving processes for existing API and formulation products
  • Developing new drug delivery systems for existing and newer active drug substances, as well as newer medical devices, mainly in the area of respiratory medicine
  • Tie-ups with independent research teams to develop new products
  • Strengthening our intellectual property, including the patenting of new products, drug delivery systems and medical devices, mainly in the area of respiratory medicine
  • Conducting clinical and bio-equivalence studies for obtaining regulatory approvals for new products and services

In addition, for our international business, our R&D team works with our strategic partners to file Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAs) in the US, and seek marketing authorizations in Europe and file product registrations in other jurisdictions.

We have earned a name for maintaining world-class quality across all our manufacturing units, products and services. We have consistently introduced more than 40 products annually, over the last decade.

We have been granted about 100 patents. Patent filing includes drug substances, drug products, platform technologies, IP on polymorphs and crystallinity, and medical devices.

We also leverage our R&D efforts to provide our customers with technical dossiers, plant layouts for pharmaceutical product manufacturing, development of processes and regulatory batches.